Mr. Elliot McKerr reports

HYTN SUCCESSFULLY RELEASES CANNABIS PRODUCTS IN GERMANY AND ACCEPTS REORDER

HYTN Innovations Inc.'s wholesale cannabis products previously exported to Germany during the prior quarter have been released for sale in the German market.

The release follows completion of required import, quality control and market release procedures for Germany's regulated medical cannabis market. Following this milestone, the company has accepted a reorder for additional wholesale product.

This milestone builds on HYTN's previously announced strategic supply framework for Germany and further demonstrates the company's ability to execute within highly regulated international medical cannabis markets.

"The successful release of product into the German market is a significant commercial milestone," said Elliot McKerr, chief executive officer of HYTN. "It validates that our GMP platform meets the stringent requirements of one of the world's most tightly regulated medical cannabis markets. The acceptance of a reorder is a positive indicator as we continue toward building recurring international revenue channels."

HYTN believes the successful German market release of this shipment further validates the commercial progress reflected in its recent financial results and supports the company's strategy of expanding pharmaceutical-grade cannabis sales into highly regulated international markets.

About HYTN Innovations Inc.

HYTN Innovations is a pharmaceutical company specializing in the formulation, manufacturing, marketing and sale of products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids. The company focuses on serving federally regulated markets by applying pharmaceutical-grade development, manufacturing and quality systems. HYTN advances products to market by identifying regulated market opportunities and leveraging its integrated development and commercialization platform.

We seek Safe Harbor.